SESN

Sesen Bio (SESN)

Sesen Bio Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SESN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/08/10	20 : 30	PR Newswire (US)	Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:SESN	Sesen Bio Inc
2023/03/07	02 : 41	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/03/07	02 : 35	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/03/04	01 : 07	Edgar (US Regulatory)	Sec Staff Action/letter (sec Staff)	NASDAQ:SESN	Sesen Bio Inc
2023/03/04	01 : 06	Edgar (US Regulatory)	Sec Staff Action/letter (sec Staff)	NASDAQ:SESN	Sesen Bio Inc
2023/03/03	02 : 07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/03/03	01 : 32	Business Wire	Sesen Bio Stockholders Approve Merger with Carisma Therapeutics	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22 : 08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22 : 03	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22 : 00	Business Wire	Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	06 : 33	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/27	22 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/02/21	23 : 05	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/21	23 : 00	Business Wire	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22 : 18	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22 : 08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22 : 04	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22 : 02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	07 : 06	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	06 : 46	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	06 : 42	Business Wire	Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting	NASDAQ:SESN	Sesen Bio Inc
2023/02/16	22 : 02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/16	22 : 00	Business Wire	Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger	NASDAQ:SESN	Sesen Bio Inc
2023/02/16	06 : 55	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:SESN	Sesen Bio Inc
2023/02/15	22 : 02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/15	22 : 00	Business Wire	BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics	NASDAQ:SESN	Sesen Bio Inc
2023/02/15	06 : 40	Edgar (US Regulatory)	Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registered on a Form S-4 (s-4mef)	NASDAQ:SESN	Sesen Bio Inc
2023/02/14	23 : 08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/14	22 : 00	Business Wire	Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger	NASDAQ:SESN	Sesen Bio Inc